High fevers and/or rashes prior to neutrophil engraftment are frequently observed after umbilical cord blood (UCB) transplantation, and the condition is referred to as pre-engraftment syndrome (PES). Few studies have evaluated the risk factors for and treatment response to PES. Therefore, we retrospectively characterized PES in 57 consecutive engrafted patients (X12 years old) who received myeloablative dual UCB transplantation. All patients received TBI (X13.2 Gy)-based myeloablative conditioning. Tacrolimus (n ¼ 35) or CYA (n ¼ 22) combined with mycophenolate mofetil was used as GVHD prophylaxis. PES was defined as the presence of noninfectious fever (X38.5 1C) and/or rash prior to or on the day of neutrophil engraftment. The incidence (95% confidence interval) of PES was 77% (66-88%). The incidence of PES was significantly higher in patients who received CYA as a GVHD prophylaxis than those who received tacrolimus (Po0.001), and this association was confirmed in the multivariate analysis. The occurrence of PES did not impact OS or tumor relapse, although it may have increased non-relapse mortality (P ¼ 0.071). The incidence of acute GHVD or treatment-related mortality was not influenced by the choice to use corticosteroids to treat PES. This study suggests that use of CYA for GVHD prophylaxis increases the risk of PES following dual UCB transplantation.
INTRODUCTION
Pre-engraftment syndrome (PES) or pre-engraftment immune reaction following umbilical cord blood (UCB) transplantation was first reported by Kishi et al. 1 in a single UCB transplantation series after reduced-intensity conditioning. PES is characterized by high-grade fever, weight gain and/or skin rash 45 days prior to engraftment. Patel et al. 2 defined PES as unexplained fever and/or unexplained fever occurring before or at the time of neutrophil recovery, and reported PES as a distinct syndrome not associated GVHD after dual UCB transplantation. However, a uniformly accepted definition of PES following UCB transplantation has yet to be established. In addition, the risk factors for PES and its clinical course have been poorly and inconsistently described. [1] [2] [3] [4] Patel et al. 2 showed that PES responds promptly to short-course corticosteroid therapy and has no association with acute GVHD (aGVHD), whereas Frangoul et al. 5 reported that PES was associated with grade II-IV or III-IV aGVHD and chronic GVHD.
In the present study, we retrospectively analyzed PES in 57 consecutive engrafted patients who received dual UCB transplantation after total-body irradiation (TBI)-based myeloablative conditioning. We focus particularly on risk factors and treatment response.
MATERIALS AND METHODS

Inclusion and exclusion criteria
We included consecutive patients aged 12 years or older who achieved successful donor engraftment following dual UCB transplantation.
All patients received a TBI-based (X13.2 Gy) myeloablative conditioning regimen for hematological malignancies at the Duke University Medical Center between 2006 and 2011. The two UCB grafts were at least 4/6 HLAmatched with the recipient, and with at least 3/6 inter-graft HLA matching (low-resolution for A and B, and high-resolution for DRB1). Patients who had a history of previous allogeneic transplantation or who had received high-dose corticosteroids (1000 mg/day) for pulmonary hemorrhage prior to engraftment were excluded. The study was approved by the institutional review board of the Duke University School of Medicine.
Definition of PES and treatment response PES was defined as non-infectious fever (X38.5 1C) and/or unexplained rash, occurring prior to or on the day of neutrophil engraftment. Neutrophil engraftment was defined as the first of 3 consecutive days on which a neutrophil count of X500/mL is achieved. Non-infectious fever was defined as a febrile episode associated with a negative blood culture. Febrile episodes that quickly responded to antibiotics without corticosteroid treatment were excluded. Drug-associated rash was excluded. The day of PES was defined as the first day of fever or rash, whichever came first. There is no uniform approach to the management of PES at our center. The decision to administer corticosteroid therapy for PES was left to the discretion of the managing physician.
Response was assessed on day 3 and day 7 after starting systemic corticosteroid treatment. CR and no response (NR) of fever in PES after treatment were defined by a temperature of o38.5 1C for more than 24 h and any other status than CR, respectively. CR, PR and NR of rash in PES after treatment were defined as complete resolution, any documented improvement and NR or worsening of rash, respectively. For patients who had both fever and rash, overall response was defined as CR if both symptoms resolved, as PR if either fever resolved or rash improved or resolved and as NR if neither fever or rash resolved. aGVHD was characterized according to standard criteria; 6, 7 however, the date of onset of aGVHD was not the same as the date of onset of PES. If PES improved with or without corticosteroid treatment, then the next date on which new signs of aGVHD occurred was the day of onset of aGVHD. If PES showed NR and progressed to aGVHD, the date of onset of PES was taken as the date of onset of aGVHD.
Statistical analysis
The primary objective of this study was to assess associations between PES and patient transplanted-related characteristics. The primary endpoint was the incidence of PES. The secondary endpoints were incidence of aGVHD, non-relapse mortality, relapse and OS. Because we included the patients who achieved successful donor engraftment, death was not a competing risk in the calculation of PES incidence. We compared the median day of PES onset based on the Wilcoxon rank sum test. We used two-tailed Fisher's exact test to assess if there were nonrandom associations between the incidences of PES and patient characteristics. We also fitted logistic regression models to assess if patient characteristics predicted PES. Univariate analysis was performed and predictors were identified separately for PES. All variables with a P-value o0.5 in the initial univariate analysis were considered potential predictors of PES in the multivariate logistic regression model. We further evaluated possible associations between PES and other symptoms by two-tailed Fisher's exact test. We estimated OS with Kaplan-Meier method and estimated the incidences of aGVHD, non-relapse mortality and relapse with the cumulative incidence method. 8 The difference in survival rate based on PES classification was assessed by log-rank test and the difference in the cumulative incidence curves were determined by the Gray test.
The patient characteristics that were assessed for an association with PES included the following: recipient age, recipient gender, disease risk at transplant (standard or high risk), disease (myeloid disease or others), HLA mismatching (4/6 þ 4/6 match or others), total nucleated cell (TNC) doses of engrafted cord blood unit (o2.5 or X2.5 Â 10 7 /kg) or, combined TNC doses of two cord blood units (o5.0 or X5.0 Â 10 7 /kg), GVHD prophylaxis (CYA or tacrolimus) and conditioning regimen (fludarabine þ TBI vs others). Standard-risk diseases were defined as AML in the first or second CR; ALL in the first or second CR; myelodysplastic syndromes; refractory anemia or refractory anemia with excess of blasts-1; Hodgkin or non-Hodgkin lymphoma in any chemotherapy-sensitive remission; and CML in the first or second chronic phase. High-risk diseases were those other than standard-risk diseases.
We collected the following information on symptoms other than PES: weight gain (410% increase over body weight just before the beginning of conditioning regimen); non-infectious diarrhea; increase in serum total bilirubin (42 mg/dL), serum aspartate amino transferase/alanine amino transferase (42 times higher than the normal upper limit) and serum creatinine levels (42 times higher than baseline just before the beginning of conditioning regimen); pulmonary edema and requirement for oxygen or pulse oximeter-measured oxygen saturation less than 92, until or at the neutrophil engraftment.
RESULTS
Patients and transplant characteristics
Of the 59 consecutive patients who met inclusion criteria for this study, two patients were excluded due to corticosteroid treatment for diffuse alveolar hemorrhage before engraftment (days 8 and 22); both died from diffuse alveolar hemorrhage at day 48 and 85. Table 1 shows patient and transplant characteristics of 57 patients. Median patient age was 28 (range, 12-58) years. Disease status at transplant was standard risk in 41 patients (72%) and high risk in 16 patients (28%). Primary disease for transplant was AML in half of the patients. Tacrolimus (n ¼ 35) or CYA (n ¼ 22) combined with mycophenolate mofetil (MMF) was used as GVHD prophylaxis. The choice of GVHD prophylaxis was determined by the active local and national UCB transplantation protocols that were active during the study period. All patients received TBI (X13.2 Gy)-based myeloablative conditioning, and half of them received a reduced toxicity myeloablative conditioning regimen consisting of fludarabine (160 mg/m 2 ) and TBI (13.5 Gy) with the use of tacrolimus as GVHD prophylaxis. The median combined TNC dose Pre-engraftment syndrome Forty-four of 57 patients met the criteria of PES (Figure 1 ). Median PES onset was at day 12 (range, 4-22), and the incidence (95% confidence interval (CI)) of PES was 77% (66%-88%). Median interval between PES and neutrophil engraftment was 11 (range, 0-26) days. Median PES onset was significantly earlier in the CYA group compared with the tacrolimus group (day 10 vs day 14, P ¼ 0.015), and the incidence of PES was significantly higher in the CYA group (incidence rate of 100%) compared with the tacrolimus group (incidence rate of 63% with 95% CI, 47-79%), whereas the incidence of PES was similar in the other stratified group ( Table 2) . The univariate logistic regression confirmed that only the use of CYA was significantly associated with the occurrence of PES; the odds ratio of PES for the CYA group vs tacrolimus group was 27.0 (95% CI, 1.4-513.3, P ¼ 0.03). We obtained the same finding even after adjusting for the possible confounding variables of age and Pre-engraftment syndrome after dual UCBT J Kanda et al conditioning regimen. Multivariate logistic regression analysis determined that the odds ratio of PES for the CYA group vs tacrolimus group was 59.6 (95% CI,1.9-4999.9, P ¼ 0.02). Body weight gain (410%), diarrhea and hyperbilirubinemia (42 mg/dL) were more frequently observed in patients with PES than in those without PES (body weight gain, 23% vs 8%; diarrhea, 32% vs 15%; hyperbilirubinemia, 14% vs 0%), though none of these differences were statistically significant ( Table 3) . Rates of transaminitis and hypoxia were low. Among the 44 patients with PES, 3 had fever only, 13 had rash only and 28 had both fever and rash; 60-70% of patients had other systemic symptoms in three categories (67%, 62% and 68%, respectively). Non-infectious diarrhea was not observed in three patients who had fever, whereas 5/13 (39%) and 9/28 patients (32%) had symptoms of non-infectious diarrhea.
Acute GVHD Median onset of acute grade II-IV aGVHD in patients with and without PES was 35 (range, 12-96) and 37 (range, 14-98), respectively, and there was no statistical difference between the two groups (P ¼ 0.609). The incidence (95% CI) of grades II-IV aGVHD at day 100 in patients with and without PES was 61% (45%-74%) and 54% (25%-76%), respectively, and that of grades III-IV aGVHD at day 100 in patients with and without PES was 36% (23-50%) and 15% (2-39%), respectively ( Figure 2 ). There was no difference in the incidences of grades II-IV (P ¼ 0.569) or grades III-IV (P ¼ 0.169) between the two groups. We also analyzed ratio of steroid refractory aGVHD in patients who developed grades II-IV aGVHD. Interestingly, we found that steroid refractory aGVHD occurred only among patients who also developed PES (non-PES vs PES group; 0% vs 40%, P ¼ 0.040).
Response to treatment Twenty-four of 44 patients with PES were treated with X1 mg/kg/ day of corticosteroids (Table 4 and Figure 1 ). Fever resolved quickly after the treatment, whereas rash improved but remained present in most patients at day 3 of treatment. Overall, corticosteroid treatment resulted in CR in 10 patients and PR in 14 patients, at day 7. In two patients, PES progressed to or overlapped with GVHD after PR to initial corticosteroid therapy. Among the 22 PES patients who could be evaluated, grade II and grade III-IV aGVHD developed in 7 and 8 patients, respectively.
Twenty of 44 patients with PES were not treated with corticosteroids; therefore, they were not evaluable for treatment response. Among the 20 patients, PES resolved without systemic corticosteroid treatment in 13 patients. Pre-engraftment syndrome after dual UCBT J Kanda et al of grade II-IV aGVHD was not influenced by treatment of PES with corticosteroids (P ¼ 0.328). The only difference in PES characteristics between patients who were treated with X1 mg/kg/day of corticosteroids or not was an increase in serum creatinine level 42 times above baseline (0% vs 20.8%, P ¼ 0.030).
OS, relapse and non-relapse mortality The OS (95% CI) at 2 years was 86% (33%-98%) and 63% (45%-77%) in patients with and without PES, respectively. This difference was not statistically significant (P ¼ 0.102) (Figure 3) .
The cumulative incidence of relapse was comparable between patients with and without PES (relapse incidence at 2 years, 15% (95% CI, 2%-39%) and 15% (95% CI, 6%-27%), respectively) ( Figure 4) . The incidence of non-relapse mortality at 2 years in patients with PES was 26% (95% CI, 13%-41%). In contrast, none of the 13 patients without PES died of treatment-related complications (Figure 4) . Among 44 patients with PES, 10 patients died of treatment-related complications without relapse: 7 died of infection, 1 of GVHD, 1 of diffuse alveolar hemorrhage and 1 of unknown cause. The incidence of treatment-related mortality was not influenced by treatment of PES with corticosteroids (P ¼ 0.346), although 5/7 patients who died from infection received systemic corticosteroid treatment for PES (parainfluenza virus 1, adenovirus 1, adenovirus þ aspergillus 1, vancomycin-resistant enterococcus 1 and multiple bacterial organisms 1) and 2/5 patients died within 100 days after transplantation.
DISCUSSION
In this study, we confirmed the high incidence of PES following UCB transplantation. In addition, we found that the use of CYA þ MMF vs tacrolimus þ MMF was a risk factor for PES. Although PES did not have a statistically significant impact on OS, patients with PES died more often because of transplant-related complications; half of the mortality was associated with infection. PES resolved in most of the patients treated with X1 mg/kg corticosteroids. However, in 13/20 patients, it also resolved in the absence of systemic corticosteroid treatment.
The incidence of PES in our cohort (77%) was comparable to that reported by Kishi et al.
1 (78%), but higher than that reported by Patel et al.
2 (31%) or Frangoul et al. 5 (20%). The definition of PES used in our study was similar to that used in the study by Patel et al.
2 , but the median onset of PES (12 (range, 4-22) days) in our study was later (9 (range, 5-12) days), and we report more PES occurrence close to neutrophil engraftment. Therefore, we recalculated the incidence of PES by excluding PES that occurred within 5 days from the neutrophil engraftment. The incidence of PES based on this definition was 63% (95% CI, 51%-75%) and was still higher than their incidence. The rate of PES by this definition was also significantly higher in the CYA group compared with the tacrolimus group. To decrease the collection bias inherent in the retrospective studies and clarify the incidence of PES in UCB transplantation, PES-related information should be prospectively collected using uniform criteria, ensuring a homogeneous patient background. The lower incidence of PES reported by Frangoul et al.
5 might be partly explained by the routine use of antithymocyte globulin and methylprednisolone (1 mg/kg day þ 1-day þ 4, 2 mg/kg day þ 5-day þ 19 or the day of neutrophil engraftment) for GVHD prophylaxis.
We found that the use of CYA þ MMF vs tacrolimus þ MMF was a risk factor for PES after myeloablative dual UCB transplantation. This may reflect the fact that the immunosuppressive effect of tacrolimus þ MMF may be stronger than that of CYA þ MMF [9] [10] [11] [12] in the early phase after transplantation. Clearly, the differential activity of tacrolimus vs CYA remains controversial, as demonstrated by the lack of difference in acute or chronic GVHD with use of either agent following mobilized PBSC transplantation. 13 Uchida et al. 3 recently showed that the addition of MMF to tacrolimus for GVHD prophylaxis in single UCB transplantation was associated with a lower incidence of PES and aGVHD than that by the use of tacrolimus alone. In addition, the incidence of PES was only 20% in the study by Frangoul et al. 5 , where anti-thymocyte globulin and high-dose methylprednisolone was used for GVHD prophylaxis. Collectively, these findings suggest that PES as well as GVHD can be prevented by intensifying immune suppression following transplantation.
The next question that arises is how to differentiate between PES and GVHD. Engraftment syndrome characterized by preengraftment fever, rash and noncardiogenic pulmonary edema has been well described in autologous transplantation. 14, 15 Hyperacute GVHD characterized by a median onset of 8 days was first described in matched sibling transplantation without GVHD prophylaxis, 16 and later it was shown that this type of GVHD was common in patients receiving transplants from a mismatched related or matched unrelated donor. 17 Therefore, there may be 2 mechanisms in PES: one related to the cytokine storm associated with the expansion of stem cells as seen in autologous transplantation and the other related to the graft-versus-host reaction against major or minor mismatched Ag by donor T cells. Thus, in order to diagnose PES and elucidate its mechanism, the potential biomarkers specific to PES are worthy of investigation. 18 The appropriateness of using stronger immunosuppression to prevent PES is a clinically relevant question. We did not find a significant difference in overall mortality between patients with and without PES. However, patients with PES were more likely to die because of transplant-related complications, mainly due to infection. Although treatment-related mortality was not different according to systemic corticosteroid treatment, 5/7 patients who died from infection received corticosteroid treatment for PES. This raises the consideration that the use of corticosteroids is perhaps better avoided unless strictly necessary. PES resolved without systemic corticosteroid treatment in 13/20 patients, suggesting the need to identify patients who require treatment for PES. However, the decision to start the corticosteroid treatment was determined by physician preference. Therefore, it is possible that our cohort contained patients who needed corticosteroids for a long period to treat resistant PES, leading to a profoundly immunocompromised state. These questions could be answered by implementing a uniform treatment strategy for PES in future studies.
Limitations of this study involving heterogeneity of the conditioning regimens and linkage of the conditioning regimen to specific GVHD prophylaxis strategies should be noted. Although myeloablative doses of TBI (X13.2 Gy) were uniformly used in our cohort, regimen intensity was slightly different. Particularly, the reduced toxicity myeloablative combination of fludarabine and TBI was linked to tacrolimus and MMF as GVHD prophylaxis. Although multivariate analysis would suggest otherwise, there remains the possibility that use of this reduced toxicity regimen, instead of the use of tacrolimus, contributed to the lower incidence of PES. Although we were unable to detect a difference in treatment-related mortality in patients treated with or without corticosteroids, it is conceivable that this finding was confounded by differences in severity of PES between the two treatment groups. As a result of the small sample size, observations drawn from the multivariate logistic regression model must be interpreted with caution. The findings described in this study should be considered hypothesis generating, and provide a foundation for further investigation on a much larger scale, using a standardized definition of PES.
In conclusion, GVHD prophylaxis with CYA was a risk factor for PES after myeloablative dual UCB transplantation in our cohort. PES did not have an impact on OS but may affect treatmentrelated complications partly due to complications of systemic corticosteroid therapy. The impact of GVHD prophylaxis (CYA vs tacrolimus) in UCB transplantation would need to be tested in a prospective trial with a uniform conditioning regimen and a common PES definition and treatment strategy.
